Squibb Company (NYSE:BMY) and Galecto Biotech AB today announced
that the companies, together with the Galecto shareholders, have entered
into an agreement that provides Bristol-Myers Squibb the exclusive
option to acquire Galecto Biotech AB and gain worldwide rights to its
lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1
development for the treatment of idiopathic pulmonary fibrosis (IPF) and
other pulmonary fibrotic conditions.
for Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis investment picks